MedTrace Logo

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

NCT04883749 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-06-08

No results posted yet for this study

Summary

The aim of this trial is to show the efficacy, safety and feasibility of acalabrutinib in a cohort of CLL-patients ≥80 years or with a FRAIL scale score \>2 (5-item questionnaire to be filled out by the patient)

Conditions

  • Chronic Lymphoid Leukemia

Interventions

BIOLOGICAL

Acalabrutinib

Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)

Sponsors & Collaborators

  • German CLL Study Group

    lead OTHER

Principal Investigators

  • Barbara Eichhorst, Prof. · Department I of Internal Medicine, University Hospital Cologne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2025-05-08
Completion
2025-05-08

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883749 on ClinicalTrials.gov